MX2016002655A - Metodo para reducir la muerte de celulas neuronales con haloalquilaminas. - Google Patents
Metodo para reducir la muerte de celulas neuronales con haloalquilaminas.Info
- Publication number
- MX2016002655A MX2016002655A MX2016002655A MX2016002655A MX2016002655A MX 2016002655 A MX2016002655 A MX 2016002655A MX 2016002655 A MX2016002655 A MX 2016002655A MX 2016002655 A MX2016002655 A MX 2016002655A MX 2016002655 A MX2016002655 A MX 2016002655A
- Authority
- MX
- Mexico
- Prior art keywords
- cell death
- haloalkylamines
- directed
- methods
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se dirige a composiciones farmacéuticas y métodos para tratar la lesión cerebral traumática (TBI). La invención también se dirige a composiciones farmacéuticas y métodos para tratar una condición transiente hipóxica y/o isquémica en el sistema nervioso central. Más específicamente, la presente invención se dirige a composiciones farmacéuticas y métodos para reducir la ocurrencia de la muerte de células neuronales en el sistema nervioso central, tal como, la reducción de la ocurrencia de la muerte de células del cerebro en el hipocampo y/o la corteza.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361874865P | 2013-09-06 | 2013-09-06 | |
PCT/US2014/054569 WO2015035308A2 (en) | 2013-09-06 | 2014-09-08 | Method of reducing neuronal cell death with haloalkylamines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016002655A true MX2016002655A (es) | 2016-06-06 |
Family
ID=52629091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016002655A MX2016002655A (es) | 2013-09-06 | 2014-09-08 | Metodo para reducir la muerte de celulas neuronales con haloalquilaminas. |
Country Status (7)
Country | Link |
---|---|
US (3) | US20160220515A1 (es) |
EP (1) | EP3041465B1 (es) |
JP (3) | JP6475733B2 (es) |
CN (2) | CN110251496A (es) |
CA (1) | CA2923476C (es) |
MX (1) | MX2016002655A (es) |
WO (1) | WO2015035308A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6475733B2 (ja) | 2013-09-06 | 2019-02-27 | ザ ユニバーシティー オブ モンタナ | ハロアルキルアミンを用いた神経細胞死の低減方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6009875A (en) | 1993-10-14 | 2000-01-04 | Berlex Laboratories, Inc. | Use of sympathetic antagonists for treatment of chronic muscle pain |
US5513661A (en) | 1993-10-14 | 1996-05-07 | Hubbard; David R. | Use of sympathetic blockade for treatment of chronic muscle pain |
US5898035A (en) | 1995-08-29 | 1999-04-27 | New York Medical College | Formulations of haloalkylamines and local anesthetic and methods for the treatment of reflex sympathetic dystrophy (RSD) |
US6284763B1 (en) | 1998-08-26 | 2001-09-04 | Queen's University At Kingston | Methods for remodeling neuronal and cardiovascular pathways |
WO2002005849A2 (en) | 2000-07-19 | 2002-01-24 | Pitmy International N.V. | Transportation of nucleic acid substances |
US6730667B2 (en) | 2001-11-26 | 2004-05-04 | William R. Deagle | Iontophoresis disc pain blocker |
US7172614B2 (en) * | 2002-06-27 | 2007-02-06 | Advanced Cardiovascular Systems, Inc. | Support structures for embolic filtering devices |
WO2004028548A2 (en) * | 2002-09-26 | 2004-04-08 | Carbomer, Inc. | Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents |
US7600349B2 (en) * | 2003-02-26 | 2009-10-13 | Unirac, Inc. | Low profile mounting system |
WO2006065555A2 (en) * | 2004-12-13 | 2006-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |
WO2007057508A2 (en) | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
WO2007062862A2 (en) | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
US20070249725A1 (en) | 2006-02-17 | 2007-10-25 | Hubbard David R | Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain |
US20110105621A1 (en) * | 2006-08-23 | 2011-05-05 | The University Of Montana | Method of reducing brain cell damage, inflammation or death |
CN103479603B (zh) | 2006-08-23 | 2016-06-22 | 蒙大拿大学 | 减轻神经元细胞损害的方法 |
US20090197969A1 (en) * | 2006-08-23 | 2009-08-06 | Poulsen David J | Method of reducing brain cell damage or death |
CN101641013B (zh) | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
US8292830B2 (en) | 2007-05-22 | 2012-10-23 | University Of Louisville Research Foundation, Inc. | Soft tissue impact assessment device and system |
US20110053913A1 (en) | 2009-06-25 | 2011-03-03 | Khem Jhamandas | Methods and Therapies for Alleviating Pain |
WO2011134075A1 (en) * | 2010-04-30 | 2011-11-03 | The University Of Western Ontario | Sox9 inhibitors |
WO2012074561A2 (en) | 2010-11-30 | 2012-06-07 | Columbia Northwest Pharmaceuticals Llc | Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders |
EP2466311A1 (en) | 2010-12-17 | 2012-06-20 | Roche Diagnostics GmbH | sFlt1 in patients with ischemic stroke |
CA2768796A1 (en) | 2011-02-22 | 2012-08-22 | Wellspring Pharmaceutical Corporation | Phenoxybenzamine assay |
WO2012162364A1 (en) * | 2011-05-23 | 2012-11-29 | New York Medical College | Phenoxybenzamine for pain |
US20140371322A1 (en) | 2013-06-13 | 2014-12-18 | Professional Compounding Centers Of America | Phenoxybenzamine Transdermal Composition |
JP6475733B2 (ja) | 2013-09-06 | 2019-02-27 | ザ ユニバーシティー オブ モンタナ | ハロアルキルアミンを用いた神経細胞死の低減方法 |
-
2014
- 2014-09-08 JP JP2016540464A patent/JP6475733B2/ja not_active Expired - Fee Related
- 2014-09-08 EP EP14843058.0A patent/EP3041465B1/en active Active
- 2014-09-08 CN CN201910642934.8A patent/CN110251496A/zh active Pending
- 2014-09-08 US US14/916,692 patent/US20160220515A1/en not_active Abandoned
- 2014-09-08 MX MX2016002655A patent/MX2016002655A/es active IP Right Grant
- 2014-09-08 CN CN201480048767.XA patent/CN105530924A/zh active Pending
- 2014-09-08 WO PCT/US2014/054569 patent/WO2015035308A2/en active Application Filing
- 2014-09-08 CA CA2923476A patent/CA2923476C/en active Active
-
2018
- 2018-10-01 US US16/148,825 patent/US10849865B2/en active Active
-
2019
- 2019-01-25 JP JP2019011177A patent/JP6636660B2/ja not_active Expired - Fee Related
- 2019-12-17 JP JP2019227012A patent/JP6865806B2/ja active Active
-
2020
- 2020-10-28 US US17/082,161 patent/US20210093586A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3041465A4 (en) | 2017-03-08 |
US20190083423A1 (en) | 2019-03-21 |
JP2020059746A (ja) | 2020-04-16 |
EP3041465A2 (en) | 2016-07-13 |
JP2019077718A (ja) | 2019-05-23 |
CA2923476A1 (en) | 2015-03-12 |
JP6475733B2 (ja) | 2019-02-27 |
WO2015035308A3 (en) | 2015-10-29 |
EP3041465B1 (en) | 2020-11-11 |
JP6865806B2 (ja) | 2021-04-28 |
CN105530924A (zh) | 2016-04-27 |
JP2016529320A (ja) | 2016-09-23 |
US20210093586A1 (en) | 2021-04-01 |
JP6636660B2 (ja) | 2020-01-29 |
WO2015035308A2 (en) | 2015-03-12 |
CA2923476C (en) | 2021-03-16 |
US20160220515A1 (en) | 2016-08-04 |
US10849865B2 (en) | 2020-12-01 |
CN110251496A (zh) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502297A1 (en) | Antibacterial compounds | |
CL2019001878A1 (es) | Compuestos de microarn y métodos de modulación de la actividad de mir-21 (divisional solicitud 201402844). | |
MX2018015656A (es) | Compuestos heterociclicos como antibacterianos. | |
GT201500294A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
CR20160542A (es) | 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
BR112016010454A2 (pt) | métodos para tratar uma taupatia | |
MX2015017253A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
PH12016500082A1 (en) | Method for promoting neuronal development and/or health | |
EP2968881A4 (en) | APPARATUS, SYSTEMS AND METHODS FOR BRAIN MEDICATION ADMINISTRATION FOR TREATING NEUROLOGICAL CONDITIONS | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
MX2017010320A (es) | Metodos de tratamiento de la infertilidad. | |
MX2016010085A (es) | Metodos para tratar lesion del cerebro leve. | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
IN2014DN09584A (es) | ||
PH12017501735A1 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
PH12014501573A1 (en) | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids | |
MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
IN2015KN00370A (es) | ||
MX2016002655A (es) | Metodo para reducir la muerte de celulas neuronales con haloalquilaminas. | |
PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
MX2018004256A (es) | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. | |
ZA201701975B (en) | C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |